Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% effective against severe disease, the company announced Friday.
‘Pretty good’ for single-dose, affordable vaccine
100 million dose US contract
And the company has been manufacturing doses for months in anticipation that it would get emergency authorization from the FDA. The company hopes to begin shipping its product the day after it gets that authorization.
Sign up here to get The Results Are In with Dr. Sanjay Gupta every Tuesday from the CNN Health team.